Phase 1 study to evaluate safety and preliminary efficacy of padeliporfin vascular targeted photodynamic therapy (VTP) in patients with locally advanced (LA) unresectable pancreatic ductal adenocarcinoma (PDAC)

被引：0
|
作者：
Abi-Jaoudeh, Nadine
Valerin, Jennifer Brooke
Imagawa, David K.
Preise, Dina
Sacks, Zachary
Cohen, Yaniv
Rothman, Julia
Brook, Keren
Morag, Eyal
Scherz, Avigdor Joshua
Krasnopolskaya, Inna
Alpert, Genia
Chung, Vincent
Melstrom, Laleh Golkar
Kessler, Jonathan
机构：
[1] Univ Calif Irvine, Div Vasc & Intervent Radiol, Dept Radiol Sci, Orange, CA USA
[2] Univ Calif Irvine, Irvine, CA USA
[3] Univ Calif Irvine, Irvine, CA USA
[4] Impact Biotech, Ness Ziona, Israel
[5] Steba Impact Biotech, Ness Ziona, Israel
[6] Weizmann Inst Sci, Dept Plants & Environm Sci, Rehovot, Israel
[7] City Hope Natl Med Ctr, Duarte, CA USA
[8] City Hope Natl Med Ctr, Med Ctr, Duarte, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4204
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Updated safety and efficacy from a Phase 1 study of RMC-6236, a RAS (ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC)
    Wolpin, B.
    Hong, D.
    Spira, A.
    Starodub, A.
    Park, W.
    Sommerhalder, D.
    Valerin, J.
    Barve, M.
    Punekar, S.
    Pelster, M.
    Herzberg, B.
    Azad, N.
    Aung, K.
    Hecht, J. R.
    Cheng, L.
    Vora, R.
    Salman, Z.
    Zhang, Y.
    Lin, T.
    Garrido-Laguna, I.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S183 - S184
  • [42] Safety and efficacy of IBI389, an anti-CLDN18.2/CD3 bispecific antibody, in patients with advanced pancreatic ductal adenocarcinoma: Preliminary results from a phase 1 study.
    Hao, Jihui
    Zheng, Li
    Dai Ruihong
    Ying Jieer
    Xu, Qi
    Wang, Li-Wei
    Jin, Yongdong
    Zhao, Ying
    Pan, Yueyin
    Liu, Lulu
    Zhang, Jun
    Sun, Yuping
    Niu, Zuoxing
    Yao, Jun
    Hua, Dong
    Zhang, Mingjun
    Dai Guanghai
    Zhang, Yulong
    Zhou, Hui
    Bi, Feng
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [43] Mitazalimab in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (PDAC): Safety data from part of the OPTIMIZE-1 study.
    Van Laethem, Jean-Luc
    Borbath, Ivan
    Prenen, Hans
    de Coana, Yago Pico
    Smith, Karin Enell
    Nordbladh, Karin
    Ellmark, Peter
    Ambarkhane, Sumeet Vijay
    Carlsson, Malin
    Cassier, Philippe Alexandre
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16237 - E16237
  • [44] Phase I study of trifluridine/tipiracil in combination with gemcitabine (gem) and nabpaclitaxel (nab-P) in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC).
    Turk, Anita Ahmed
    Helft, Paul R.
    Sehdev, Amikar
    Shahda, Safi
    Loehrer, Patrick J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 731 - 731
  • [45] A phase I study of gemcitabine/nab-paclitaxel/S-1 chemotherapy in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma.
    Chang, Chen
    Li, Xiaofen
    Cheng, Ke
    Cai, Zhaolun
    Xiong, Junjie
    Lv, Wanrui
    Li, Ruizhen
    Zhang, Pei
    Cao, Dan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16261 - E16261
  • [46] A multicenter, open-label phase II study to evaluate the efficacy and safety of pimicotinib (CSF-1R inhibitor) in combination with chemotherapy with or without toripalimab in patients (pts) with advanced pancreatic ductal adenocarcinoma (aPDAC)
    Zhang, X.
    Cui, J.
    Quan, M.
    Zhang, T.
    Cao, D.
    Li, Z.
    Yang, D. T. C.
    Zhu, X.
    Chen, Y.
    Liang, P.
    Yao, L.
    Wang, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S934 - S935
  • [47] Can Stereotactic Body Radiation Therapy Be a Viable and Efficient Therapeutic Option for Unresectable Locally Advanced Pancreatic Adenocarcinoma? Results of a Phase 2 Study
    Comito, Tiziana
    Cozzi, L.
    Clerici, E.
    Franzese, C.
    Tozzi, A.
    Iftode, C.
    Navarria, P.
    D'Agostino, G.
    Rimassa, L.
    Carnaghi, C.
    Personeni, N.
    Tronconi, M. C.
    De Rose, F.
    Franceschini, D.
    Ascolese, A. M.
    Fogliata, A.
    Tomatis, S.
    Santoro, A.
    Zerbi, A.
    Scorsetti, M.
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2017, 16 (03) : 295 - 301
  • [48] PHASE II STUDY OF ORAL S-1 AND CONCURRENT RADIOTHERAPY IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED PANCREATIC CANCER
    Sudo, Kentaro
    Yamaguchi, Taketo
    Ishihara, Takeshi
    Nakamura, Kazuyoshi
    Hara, Taro
    Denda, Tadamichi
    Tawada, Katsunobu
    Imagumbai, Toshiyuki
    Araki, Hitoshi
    Sakai, Mitsuhirc
    Hatano, Kazuo
    Kawakami, Hiroyuki
    Uno, Takashi
    Ito, Hisao
    Yokosuka, Osamu
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 80 (01): : 119 - 125
  • [49] Phase I study of S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic carcinoma.
    Sudo, K
    Yamaguchi, T
    Ito, H
    Ishihara, T
    Nakamura, K
    Kawakami, H
    Uno, T
    Saisho, H
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 354S - 354S
  • [50] Phase I study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer
    Sudo, Kentaro
    Yamaguchi, Taketo
    Ishihara, Takeshi
    Nakamura, Kazuyoshi
    Shirai, Yoshihiko
    Nakagawa, Akihiko
    Kawakami, Hiroyuki
    Uno, Takashi
    Ito, Hisao
    Saisho, Hiromitsu
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 67 (01): : 219 - 224
12345